Literature DB >> 2324546

The association of Shiga toxin and other cytotoxins with the neurologic manifestations of shigellosis.

S Ashkenazi1, K R Cleary, L K Pickering, B E Murray, T G Cleary.   

Abstract

The neurologic symptoms in human shigellosis have often been attributed to Shiga toxin, although its exact role has not been determined. By use of a [3H] thymidine-labeled HeLa cell assay, cytotoxic activity was demonstrated in stool but not cerebrospinal fluid or serum from five patients with shigellosis presenting with seizures or encephalopathy. Bacterial isolates produced 16.0-88.2 CD50 (50% cytotoxic dose) of cytotoxin/mg of protein. The toxin activity in stool and the cytotoxic activity of the isolates were not neutralized by antiserum to purified Shiga toxin. DNA hybridization studies showed that Shigella isolates from these patients lacked the structural genes for Shiga toxin. The cytotoxin produced was also distinct from Shiga-like toxins I and II. Sonicates of the Shigella strains injected intraperitoneally into mice caused lethargy and lethality. The toxin activity was heat-labile and sensitive to trypsin, indicating that its active component is protein. Ultrafiltration and gel filtration chromatography showed a molecular mass of 100-125 kDa. Thus Shiga toxin production is not essential for the development of neurologic manifestations of shigellosis; other toxic products may play a role.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2324546     DOI: 10.1093/infdis/161.5.961

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

Review 1.  Genetic basis of virulence in Shigella species.

Authors:  T L Hale
Journal:  Microbiol Rev       Date:  1991-06

2.  An update on vaccines against Shigella.

Authors:  Shai Ashkenazi; Dani Cohen
Journal:  Ther Adv Vaccines       Date:  2013-09

3.  Encephalopathy associated with enteroinvasive Escherichia coli 0144:NM infection.

Authors:  M Ephros; D Cohen; M Yavzori; N Rotman; B Novic; S Ashkenazi
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

4.  Early postoperative seizures after vocal fold surgery attributed to shigellosis.

Authors:  Gennady Bregman; Yonatan Lahav; Yelena Kishinevsky; Galina Grinevich; Tiberiu Ezri; Alexander Dukhan
Journal:  Anaesth Rep       Date:  2019-06-11

5.  Antibodies to shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae 1 dysentery.

Authors:  M M Levine; J McEwen; G Losonsky; M Reymann; I Harari; J E Brown; D N Taylor; A Donohue-Rolfe; D Cohen; M Bennish
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

6.  Characterization of Shigella dysenteriae type 1 capsular polysaccharide by immunochemical methods.

Authors:  K Nasher; I Ciznár
Journal:  Folia Microbiol (Praha)       Date:  1998       Impact factor: 2.099

7.  Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice.

Authors:  V L Tesh; J A Burris; J W Owens; V M Gordon; E A Wadolkowski; A D O'Brien; J E Samuel
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

8.  Detection and analysis of CRISPRs of Shigella.

Authors:  Xiangjiao Guo; Yingfang Wang; Guangcai Duan; Zerun Xue; Linlin Wang; Pengfei Wang; Shaofu Qiu; Yuanlin Xi; Haiyan Yang
Journal:  Curr Microbiol       Date:  2014-09-09       Impact factor: 2.188

9.  Fatal cerebral edema associated with serine deficiency in CSF.

Authors:  Irene M L W Keularts; Piet L J M Leroy; Estela M Rubio-Gozalbo; Leo J M Spaapen; Biene Weber; Bert Dorland; Tom J de Koning; Nanda M Verhoeven-Duif
Journal:  J Inherit Metab Dis       Date:  2010-03-19       Impact factor: 4.982

10.  Fulminant Shigellosis in a HIV Patient.

Authors:  Siang Mei Sally Ooi
Journal:  Case Rep Infect Dis       Date:  2015-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.